Expanded clearance allows the system to support hair removal and vascular lesion treatment using multiple wavelength configurations.
Wingderm, a manufacturer of medical aesthetic devices, announced that its Lasermach system has received expanded clearance from the US Food and Drug Administration (FDA), allowing use across all three wavelengths.
With the latest clearance, Lasermach is now approved for use with mixed- and single-wavelength handpieces.
Expanded Indications
The mixed-wavelength handpiece (755 nm, 808 nm, and 1064 nm) is cleared for temporary hair reduction and for the treatment of benign vascular and vascular-dependent lesions.
Single-wavelength handpieces (755 nm, 808 nm, or 1064 nm) are cleared for hair removal and permanent hair reduction across all Fitzpatrick skin types (I–VI).
Compared to earlier configurations, the system can now be used across a broader range of skin tones and hair types, according to a release from the company. “This increased versatility enables medspas to satisfy a wide range of hair removal demands using a single platform, simplifying device selection and daily operations,” reads the release.
Industry presentation
Wingderm says it plans to showcase the Lasermach system at the American Academy of Dermatology Annual Meeting, scheduled for March 27–29 in Denver.
Wingderm, founded in 2016, develops photoelectric medical aesthetic devices and reports that its systems are used in multiple countries worldwide.
Photo caption: Lasermach
Photo credit: Wingderm
